

administration of indole-3-carbinol for at least 3 or at least 6 days, let alone the administration of an oral dosage of indole-3-carbinol of 0.5 to 3 g/m<sup>2</sup> per day.

The pending claims are believed to be patentable for at least the reasons discussed above. However, Applicants reserve the right to separately address the patentability of additional elements in the claims in the future, should that become necessary.

## AUTHORIZATION

The Commissioner is hereby authorized to charge any additional fees which may be required for consideration of this Amendment to Deposit Account No. **50-3732**, Order No. 13566.105014. In the event that an extension of time is required, or which may be required in addition to that requested in a petition for an extension of time, the Commissioner is requested to grant a petition for that extension of time which is required to make this response timely and is hereby authorized to charge any fee for such an extension of time or credit any overpayment for an extension of time to Deposit Account No. **50-3732**, Order No. 13566.105014.

Respectfully submitted,  
King & Spalding, LLP

Dated: February 19, 2009

By: /michael willis/  
Kenneth H. Sonnenfeld / Michael A. Willis  
Reg. No. 33,285 / Reg. No. 53,913

Correspondence Address:  
Customer Number 65989  
King & Spalding  
1185 Avenue of the Americas  
New York, NY 10036-4003  
(212) 556-2100 Telephone  
(212) 556-2222 Facsimile